| [1] |
Carom AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation.Developed with the special contribution of the European Heart Rhythm Association[J]. Eur Heart J, 2012, 33(21): 2719-2747.
|
| [2] |
January CT,Wann LS,Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society[J]. J Am Coll Cardiol, 2014, 64(21): 2305-2307.
|
| [3] |
National Clinical Guideline Centre (UK). Atrial Fibrillation: the management of atrial fibrillation. London: National Institute for Health and Care Excellence (UK), 2014.
|
| [4] |
Verma A,Cairns JA,Mitchell LB, et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation[J]. Can J Cardiol, 2014, 30(12): 1495.
|
| [5] |
You JJ, Singer DE, Howard PA, et al. American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest, 2012, 141(2 Suppl): e531S-e575S.
|
| [6] |
胡大一，郭艺芳．心房颤动抗凝治疗中国专家共识[J]．心脑血管病防治，2012，12(3): 174.
|
| [7] |
Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation Cohort study[J]. Eur Heart, 2012, 33(12): 1500-1510.
|
| [8] |
Boriani G, Botto GL, Padeletti L, et al. Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring[J]. Stroke, 2011, 42(6): 1768-1770.
|
| [9] |
Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study[J].BMJ, 2011, 31: 342.
|
| [10] |
Olesen JB, Torp-Pedersen C, Hansen ML, et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study[J]. Thromb Haemost, 2012, 107(6): 1172-1179.
|
| [11] |
Chao TF, Lin YJ, Tsao HM, et al. HADS(2) and CHA(2)DS(2)-VASc scores in the prediction of clinical out-comes in patients with atrial fibrillation after catheter ablation[J].Am Coll ardiol, 2011, 58(23): 2380-2385.
|
| [12] |
Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results om the National Registry of Atrial Fibrillation (NRAF)[J]. Am Heart, 2006, 151(3): 713-719.
|
| [13] |
Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey[J]. Chest, 2010, 138(5): 1093-1100.
|
| [14] |
Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Antic-oagulation and Risk Factors in Atrial Fibrillation) study[J]. Am Coll Cardiol, 2011, 58(4): 395-401.
|
| [15] |
Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drugs/alcohol concomitantly)score[J]. Am Coll Cardiol, 2011, 57(2): 173-180.
|
| [16] |
Olesen JB, Lip GY, Hansen PR, et al. Bleeding risk in 'real world’ patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort[J]. Thromb Haemost, 2011, 9(8): 1460-1467.
|
| [17] |
Gallego P, Rolda´ n V, Torregrosa JM, et al. Relation of the HAS-BLED bleeding risk score to major bleeding cardiovascular events and mortality in anticoagulated patients with atrial fibrillation[J]. Circ Arrhythm Electrophysiol, 2012, 5(2): 312-318.
|
| [18] |
Mavaddat N,Roalfe A,Fletcher K, et al. Warfarin versus aspirin for prevention of cognitive decline in atrial fibrillation: randomized controlled trial (Birmingham atrial fibrillation treatment of the aged study)[J]. Stroke, 2014, 45(5): 1381-1386.
|
| [19] |
Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation[J]. N Engl Med, 2009, 360(20): 2066-2078.
|
| [20] |
Wallentin L, Yusuf S, Ezekowitz MD, et al. RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial[J]. Lancet, 2010, 376(9745): 975-983.
|
| [21] |
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl Med, 2011, 365(10): 883-891.
|
| [22] |
Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation[J]. N Engl Med, 2011, 364(9): 806-817.
|
| [23] |
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation[J].N Engl Med, 2011, 365(11): 981-992.
|